Wingspan announces that Actelion Pharmaceuticals, a top 20 biopharmaceutical company, has selected Wingspan eTMF as its official electronic trial master file.
Wingspan announces that Actelion Pharmaceuticals, a top 20 biopharmaceutical company, has selected Wingspan eTMF as its official electronic trial master file. The company, based in Switzerland, outlined specific goals of the trial master file implementation including providing key management metrics, increasing inspection readiness, saving time, reducing costs and increasing eTMF quality. Wingspan eTMF allows Actelion access to comprehensive metrics and reports in real time and integrates with the company’s existing applications. Because Wingspan eTMF is cloud-based, Actelion’s clinical trial specialists will have 24-hour access to trial related documents managed by Wingspan eTMF and easy external access from any location for all users, including CROs and partners.
Additionally, Actelion selected Wingspan given the technology company’s specialized focus on eTMF and strong client references from Pfizer and ICON, plc.
Wingspan Principal and CEO, Troy Deck said, "We are thrilled to have Actelion as a client and extraordinarily excited to be able to support their worldwide research through the use of our eTMF platform. Wingspan’s technical excellence and focus on trial efficiency aligns well with Actelion’s core values of Innovation and Results-Driven approach. Working together, we will continue to shape and improve the TMF landscape through refinement and expansion of our powerful and distinct capabilities."
After signing contractual agreements last week, Wingspan project managers joined the Actelion team in Switzerland to kick-off the implementation project. Wingspan will work with Actelion to launch its pilot project in mid-February with a larger rollout in June.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.